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Introduction
Genetic polymorphisms of CYP2C9 significantly influence the pharmacokinetics and pharmacodynamics of some drugs, which might result in adverse drug effects and therapeutic failure. CYP2C9 constitutes ～20% of the CYP protein content in human liver microsomes, and it is responsible for clearing ～15% of drugs that undergo Phase I metabolism (Schwarz, 2003; Van Booven et al., 2010) . Accumulating evidences indicate that CYP2C9 ranks amongst the most important drug metabolizing enzymes in humans. This enzyme hydroxylates weakly acidic or neutral drugs of diverse therapeutic categories, including the hypoglycemic agents tolbutamide and glimepiride, the nonsteroidal anti-inflammatory drugs flurbiprofen and diclofenac, the antihypertensive losartan, the diuretic torsemide, the anticonvulsant phenytoin, and the anticoagulant warfarin (Rettie and Jones, 2005) . Genetic polymorphisms of CYP2C9 can lead to wide inter-individual variations in drug metabolism (Thakkar et al., 2012) . To date, at least 58 allelic variants of CYP2C9 have been reported, and the majority of these are found in Asian populations (http://www.cypalleles.ki.se/cyp2c9.htm). Among them, CYP2C9 alleles *2 and *3, the most common allelic variants, have been well studied both in vivo and in vitro over the last few years (Tang et al., 1999; Yasar et al., 2001; Ali et al., 2009 (Dai et al., 2014b (Clozel et al., 1994; Weber et al., 1996) . It decreases both pulmonary and systemic vascular resistance, thereby increasing cardiac output without increasing the heart rate (Rubin et al., 2002; Farber and Loscalzo, 2004) . BOS was approved by US FDA in 2001 and is the first oral drug used for the successful treatment of pulmonary arterial hypertension (Motte et al., 2006) . BOS is extensively metabolized in the liver by the CYP isoenzymes 2C9 and 3A4 to give three metabolites namely, the HYBOS (Ro 48-5033), the phenol metabolite (Ro 47-8634), and the hydroxyl phenol metabolite (Ro 64-1056) (Weber et al., 1999) , of which only HYBOS is pharmacologically active (Actelion Pharmaceuticals Ltd., data on file).
Hydroxylation at the t-butyl group by CYP2C9 and CYP3A4 yields metabolite Ro 48-5033, a metabolite that binds to endothelin receptors but with half the affinity of that of parent BOS, and its contribution to the pharmacological activity of BOS is limited to up to 20% (Actelion Pharmaceuticals Ltd., data on file Losartan (30μl of a 1μg/ml in methanol solution) as an internal standard was added to the mixture followed by the addition of 0.4mL of acetonitrile, which was then vortexed for 2 min and centrifuged at 13,000 rpm at 4 °C for 10min. The supernatant was 1:1 diluted with water and 5µL mixture injected into the UPLC-MS/MS system for analysis.
Chromatographic conditions. The chromatographic separation was carried out using an ACQUITY UPLC-MS/MS and performed on a Waters ACQUITY UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm particle size, Waters, USA) and inline 
Discussion
To better understand the function of CYP2C9 allele on the metabolism of BOS, we screened the 38 variants with the recombinant insect microsomes. We found that some of the variants showed decreased enzyme activity as the previous studies reported, but some of them cause increased or no change enzyme activity which are not in accordance with the previous researches (Dai et al., 2014a; Wang et al., 2014) . found that CYP2C9*8 is associated with lower clearance for phenytoin and warfarin (Allabi et al., 2005a; Allabi et al., 2012) . In present study, we found that CYP2C9*8 showed significant decrement in Vmax (14.3%) which caused lower clearance for BOS. Apparent discrepancies regarding CYP2C9*8 might be explained by a substrate-dependent activity, the R150H substitution potentially altering an The CYP2C9*11 allele is associated with decreased enzyme activity compared to the wild type variant, as observed in studies about losartan and tolbutamide metabolism (Blaisdell et al., 2004; Allabi et al., 2005b) . But in a previous study, it also has been suggested that CYP2C9*11 might not be significantly associated with a slightly lower dose requirement of warfarin (King et al., 2004) . In our study, CYP2C9*11 allele exhibited significantly increased catalytic activity in BOS metabolism compared to wild-type CYP2C9*1.
The CYP2C9*13 (Leu90Pro) variant allele occurs is approximately 2% of the Chinese populations (Si et al., 2004) . CYP2C9*13 also exhibited reduced metabolic activity toward tolbutamide and diclofenac in vitro (Guo et al., 2005b) . In present study, CYP2C9*13 produces a protein with a higher Km, lower Vmax and lower intrinsic clearance than the CYP2C9*1 allele. However, the Leu90Pro substitution in CYP2C9*13 is located in a nonhaeme-binding region far from the substrate binding pocket (Guo et al., 2005a) . Thus, the reason for the CYP2C9*13-mediated reduction in drug-metabolizing capability is unclear.
CYP2C9*14, CYP2C9*16 and CYP2C9*19 were found in Southeast Asians and reported to exhibit moderately or markedly decreased intrinsic clearance of tolbutamide in vitro (DeLozier et al., 2005) . In our study, only CYP2C9*19 markedly decreases the intrinsic clearance of BOS (1.65%) and caused lower value of Vmax (2.1%) relative to wild-type consistent with the previous observations. Although the functional significance of CYP2C9*23 was unknown from Veenstra DL' study (Veenstra et al., 2005) , our results showed that this allele without significant change in clearance for BOS. Studies showed that CYP2C9*27 (Arg150Leu) and CYP2C9*29 (Pro279Thr) showed similar catalytic activities against diclofenac compared with the wild type (Maekawa et al., 2006) . However, in our study CYP2C9*27 cause 241.32% increasing in the clearance of BOS. CYP2C9*31 is predicted to be a functional defective allele (Matimba et al., 2009) which is a little surprising that our results showed that CYP2C9*31 without significant change in clearance. Two variations, CYP2C9*33 and CYP2C9*34, were first detected in 724
Japanese individuals (Yin et al., 2008) . CYP2C9*33 showed lower intrinsic clearance of diclofenac in vitro, while CYP2C9*34 have no substantial effect (Yin et al., 2008) .
In this study, a similar result was obtained, in which that CYP2C9*33 showed lower intrinsic clearance of BOS (10.84) in vitro, while CYP2C9*34 have no significant changes.
In our study, the CYP2C9*36 causes a significant increasing in Vmax (2.0 fold) and little or no change in the Km for catalysis of BOS which that cause significant increasing clearance. Our results showed that R124Q (CYP2C9*42), R124W
(CYP2C9*43), which also showed decreased intrinsic clearance for BOS in vitro and these data are in accordance with the study performed by Dai, et al(Dai et al., 2014b) .
However, the relative enzymatic activities among these CYP2C9 variants present a much different pattern when the drug BOS was used as the substrate. BOS is extensively metabolized in the liver by the CYP isoenzymes 2C9 and 3A4
to give three metabolites namely, the Ro 48-5033, Ro 47-8634, and Ro 64-1056 (Weber et al., 1999) . Hydroxylation at the t-butyl group by CYP2C9 and CYP3A4 
